ClinicalTrials.gg
CompletedNCT04616027Updated May 10, 2024Results posted

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

A Phase 1 interventional study of PF-06882961 20 mg in Diabetes Mellitus, Type 2, Renal Impairment and Healthy, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Diabetes Mellitus, Type 2 by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 2 · Pfizer.

Enrollment
44th of 79
42 · median 50
Started
2021
with 2 others
Phase 1
47 of 80
none open now
Registered
72nd of 80
by date

Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 44th largest by enrollment of the 79 interventional ones that give a count, is one of 3 that started in 2021, is one of 47 in phase 1, and was the 72nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 80 studies in Diabetes Mellitus, Type 2 by Pfizer are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Diabetes Mellitus, Type 2 by Pfizer, or all of them as a file.
02

Study summary

This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Renal Impairment
  • Healthy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable renal function (for participants not on dialysis) defined as ≤25% difference between 2 measurements of (as calculated by the sponsor-identified central laboratory using the CKD-EPI equation)1 obtained at Screening visits S1 and S2. The average of the 2 eGFR values obtained from S1 and S2 will be used for study enrollment and assignment to appropriate renal function group. Note: participants on dialysis will be placed in Group 5 regardless of eGFR from S1 and S2 (S2 is optional for dialysis participants only).
  • Male and female participants must be ≥18 years of age, inclusive, at the time of signing the document (ICD).
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures, including the ability to perform self-monitoring blood glucose at a frequency deemed appropriate by the investigator.
  • (BMI) of ≥18.0 kg/m2 and \<45.4 kg/m2; and a total body weight >50 kg (110 lb).
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Additional Inclusion Criteria for Healthy Participants with Normal Renal

Function (Group 1):

  • No abnormalities identified by a detailed medical history, full physical examination, including blood pressure (BP) and pulse rate measurement, standard 12-lead and clinical laboratory tests.
  • Normal renal function (mean eGFR ≥90 mL/min) based on an average of measures from Screening visits S1 and S2.
  • Demographically comparable to participants with impaired renal function:

    1. A body weight within ±15 kg of the mean body weight of the pooled renal impairment groups (Groups 3, 4, and 5), as provided by sponsor;
    2. An age within ±10 years of the mean age of the pooled renal impairment groups (Groups 3, 4 and 5), as provided by sponsor;
    3. Attempts will be made to ensure that the male to female distribution in Group 1 is comparable to that in the pooled renal impairment groups (Cohorts 3, 4, and 5).

      Additional Inclusion Criteria for T2DM Participants with Normal Renal

      Function (Group 2):

  • A prior diagnosis of T2DM with an ≥6% and ≤10.5%, at Screening visit S1, confirmed by a single repeat, if deemed necessary.
  • Normal renal function (mean eGFR ≥90 mL/min) based on an average of measures from Screening visits S1 and S2.
  • Prohibited prior/concomitant medications.
  • Demographically comparable to participants with impaired renal function:

    1. A body weight within ±15 kg of the mean body weight of the pooled renal impairment groups (Groups 3, 4, and 5), as provided by sponsor;
    2. An age within ±10 years of the mean age of the pooled renal impairment groups (Groups 3, 4, and 5), as provided by sponsor;
    3. Attempts will be made to ensure that the male to female distribution in Group 2 is comparable to that in the pooled renal impairment groups (Cohorts 3, 4, and 5).

Additional Inclusion Criteria for T2DM Participants with Impaired Renal Function (Groups 3-5):

  • A prior diagnosis of T2DM with an HbA1c ≥6% and ≤10.5%, at Screening visit S1, confirmed by a single repeat, if deemed necessary.
  • Meet the eGFR criteria listed for Groups 3, 4, or 5 (for participants not on dialysis) in Table 1 based on an average of measures from Screening visits S1 and S2.
  • Stable concomitant medications, as defined in Section 6.5, for the management of medical conditions relevant to an individual participant's medical history. Participants receiving fluctuating concomitant medications/treatments may be considered, on a case-by-case basis with input from sponsor, if the underlying disease is stable.
  • For Group 5 participants on dialysis only, participants must have required hemodialysis for at least 6 weeks and need dialysis sessions 3 times per week

Exclusion criteria

Exclusion Criteria:

  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, or any area of intestinal resection, active inflammatory bowel disease or pancreatic insufficiency). NOTE: subjects who have undergone cholecystectomy and/or appendectomy are eligible for this study so long as the surgery occurred more than 6 months prior to Screening;
  • Any not considered cured (except basal cell carcinoma and squamous cell carcinoma of the skin); a participant is considered cured if there has been no evidence of cancer recurrence in the previous 5 years.
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2), or participants with suspected MTC per the investigator's judgement.
  • History of chronic or acute pancreatitis within 5 years.
  • Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes.
  • History of diabetic ketoacidosis.
  • History of myocardial infarction, unstable angina, arterial revascularization, stroke, Functional Class II-IV heart failure, or within 3 months of Screening visit S1.
  • Urinary incontinence.
  • Participants with acute renal disease.
  • Renal allograft recipients.
  • Participants with other disease, in the judgment of the investigator that may affect the safety of the participant or that may affect the PK of PF 06882961.
  • Prohibited prior/concomitant medications.
  • Compliance with details regarding prohibited prior/concomitant medications.
  • Previous administration with an drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of IP used in this study (whichever is longer).
  • Known prior participation in a trial involving PF 06882961 or known or intolerance to a GLP-1R agonist.
  • Screening standard 12-lead that demonstrates a clinically relevant abnormality that requires further diagnostic evaluation or intervention (eg, new, clinically relevant arrhythmia, conduction disturbance, findings suggestive of ischemia). A potential participant whose pre-dose ECG (on Day 1, 0 hour) demonstrates a clinically relevant abnormality that requires further diagnostic evaluation or intervention will be considered a screen failure.
  • A positive COVID-19 test in the screening period.
  • A positive urine drug test (or other type of drug test in anuric participants on dialysis only).
  • Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific central laboratory and confirmed by a single repeat test, if deemed necessary:

    • (AST) or alanine aminotransferase (ALT) level ≥2 × (ULN);
    • Total level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.
    • Fasting C-peptide \<0.8 ng/mL.
    • Fasting plasma glucose (FPG) >270 mg/dL (15 mmol/L) at screening (S1).
  • History of regular alcohol consumption exceeding 7 drinks/week for female participants or 14 drinks/week for male participants (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months before screening.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia only if heparin is planned to flush intravenous catheters.

Additional Exclusion Criteria for Healthy Participants with Normal Renal

Function (Group 1):

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including clinically relevant and significant drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Use of prescription or non-prescription drugs and dietary and herbal supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of IP). As an exception, ibuprofen or acetaminophen may be used at doses of ≤1 g/day. Limited use of non-prescription medications that are not believed to affect participant safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
  • Screening seated systolic blood pressure (SBP) >140 mmHg or diastolic blood pressure (DBP) >90 mmHg, following at least 5 minutes of supine rest. If SBP is >140 mmHg or DBP >90 mmHg, the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
  • Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific central laboratory and confirmed by a single repeat test, if deemed necessary:

≥6.0% at Screening visit S1; FPG ≥126 mg/dL at screening (S1); Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥1.5 × upper limit of normal (ULN). Additional Exclusion Criteria for T2DM Participants with Normal Renal

Function (Group 2):

  • At Screening, seated systolic blood pressure (SBP) ≥160 mm Hg and/or diastolic blood pressure (DBP) ≥105 mm Hg after ≥5minute of seated rest, with a single repeat permitted to assess eligibility, if needed, at each of these 2 visits.

Additional Exclusion Criteria for T2DM Participants with Impaired Renal

Function (Groups 3-5) only:

  • At Screening, persistent severe, uncontrolled hypertension; for example: seated systolic blood pressure (SBP) ≥180 mm Hg and/or diastolic blood pressure (DBP) ≥105 mm Hg after ≥5minute of seated rest, with a single repeat permitted to assess eligibility, if needed, at each of these 2 visits: For subjects with SBP ≥160 mm Hg or DBP ≥100 mm Hg, the period between Screening and Day 1 must be used to refine the doses of the agents used for management of blood pressure with the aim to have stable BP on Day 1;.
  • For participants in Group 5 on Dialysis only: Hemodynamic instability during or at the conclusion of dialysis during the 2 weeks prior to dosing, as marked by symptomatic hypotension.

Criteria for Dosing on Day 1

Participants will progress to dosing on Day 1 provided they have satisfied all the following criteria:

  • In women of , urine pregnancy test on Day -1 is negative;
  • Cohort 1 and Cohort 2 only: Approval from the sponsor must be obtained before proceeding with dosing participants in either Cohort 1 or Cohort 2;
  • Cohorts 2-5 only: Participants must have measurement on Day 1 of SBP \<160 mm Hg and DBP \<100 mm Hg; A single repeat assessment is permitted, to confirm that the above criterion is met [and in such cases, the repeat assessment overrides initial results].
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Healthy participants with normal renal function

    This arm includes participants with normal renal function who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1

    Drug: PF-06882961 20 mg

  • Experimental
    Participants with T2DM with normal renal function

    This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with normal renal function who will receive an oral dose of PF-06882961 20 mg on Day 1

    Drug: PF-06882961 20 mg

  • Experimental
    Participants with T2DM with mild renal impairment

    This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with mild renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1

    Drug: PF-06882961 20 mg

  • Experimental
    Participants with T2DM with moderate renal impairment

    This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with moderate renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1

    Drug: PF-06882961 20 mg

  • Experimental
    Participants with T2DM with severe renal impairment

    This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with severe renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1

    Drug: PF-06882961 20 mg

Interventions

  • PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961

    Cmax was the maximum observed plasma concentration and was directly observed from data.

    Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3

  2. Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-06882961

    AUCinf was defined as area under the plasma concentration-time curve from time zero to infinity.

    Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3

  3. Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-06882961

    AUClast was area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.

    Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3

  4. Fraction Unbound (fu) of Plasma PF-06882961

    Fu was defined as fraction of unbound drug in plasma.

    Time frame: 0 (pre dose), 4 hours (post dose) on Day 1

Secondary outcomes

  1. Maximum Observed Concentration of Unbound Drug (Cmax,u) of Plasma PF-06882961

    Cmax,u was defined as maximum observed concentration of unbound drug.

    Time frame: 0 (pre dose), 4 hours (post dose) on Day 1

  2. Unbound Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf,u) of Plasma PF-06882961

    AUCinf,u was defined as unbound area under the plasma concentration-time profile from time zero extrapolated to infinite time.

    Time frame: 0 (pre dose), 4 hours (post dose) on Day 1

  3. Unbound Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,u) of Plasma PF-06882961

    AUClast,u was defined as unbound area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration.

    Time frame: 0 (pre dose), 4 hours (post dose) on Day 1

  4. Apparent Clearance (CL/F) of Plasma PF-06882961

    Apparent Clearance After Oral Dose (CL/F) was defined as apparent clearance after oral dose on the last day of treatment period.

    Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3

  5. Apparent Clearance of Unbound Drug After Oral Administration (CLu/F) of Plasma PF-06882961

    CLu/F was defined as apparent clearance of unbound drug.

    Time frame: 0 (pre dose), 4 hours (post dose) on Day 1

  6. Apparent Volume of Distribution (Vz/F) of Plasma PF-06882961

    Vz/F was defined as apparent volume of distribution.

    Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3

  7. Unbound Vz/F (Vz,u/F) of Plasma PF-06882961

    Vz,u/F was defined as apparent volume of distribution of unbound drug.

    Time frame: 0 (pre dose), 4 hours (post dose) on Day 1

  8. Time of Observed Maximum Plasma Concentration (Tmax) of Plasma PF-06882961

    Tmax was defined as time to maximum observed concentration. Observed directly from data as time of first occurrence.

    Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3

  9. Terminal Elimination Half-Life (T1/2) of Plasma PF-06882961

    Plasma terminal elimination half-life (T1/2) is the time measured for the plasma concentration to decrease by one half at the terminal phase.

    Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3

  10. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse event (TEAE) means event between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of death; inpatient hospitalization; life-threatening experience; disability; congenital anomaly or deemed significant for any other reason.

    Time frame: From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)

  11. Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

    Laboratory test abnormalities included hematology, chemistry and urinalysis.

    Time frame: From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)

  12. Number of Participants With Abnormal Vital Signs

    The vital signs were measured included pulse rate (beats/min) and blood pressure (mmHg).

    Time frame: From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)

  13. Number of Participants With Abnormal Electrocardiograms (ECGs)

    ECG parameters included QTCF, PR interval, and QRS interval.

    Time frame: From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)

07

Results

Posted May 10, 2024

Participant flow

Participant flow — Overall Study
MilestoneHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Started87888
Completed87888
Not completed00000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961

Cmax was the maximum observed plasma concentration and was directly observed from data.

Time frame:
0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961
nanograms/milliliter (ng/mL)Healthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Maximum Observed Plasma Concentration (Cmax) of Plasma PF-0688296138.80 ± 2838.67 ± 5839.19 ± 4256.68 ± 2839.18 ± 50
Statistical analysis
  • Healthy and Normal Renal Function vs T2DM Normal Renal Function · Ratio (test/reference) of adjusted means: 99.67 · 90% CI 70.15 to 141.60
  • T2DM Normal Renal Function vs T2DM Mild Renal Impairment · Ratio (test/reference) of adjusted means: 101.34 · 90% CI 70.51 to 145.63
  • T2DM Normal Renal Function vs T2DM Moderate Renal Impairment · Ratio (test/reference) of adjusted means: 146.56 · 90% CI 103.16 to 208.22
  • T2DM Normal Renal Function vs T2DM Severe Renal Impairment · Ratio (test/reference) of adjusted means: 101.31 · 90% CI 71.31 to 143.92
PrimaryArea Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-06882961

AUCinf was defined as area under the plasma concentration-time curve from time zero to infinity.

Time frame:
0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-06882961
nanograms*hour/milliliter (ng*hr/mL)Healthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-06882961362.4 ± 30404.8 ± 49487.0 ± 19543.2 ± 48408.8 ± 46
Statistical analysis
  • Healthy and Normal Renal Function vs T2DM Normal Renal Function · Ratio (test/reference) of adjusted means: 111.71 · 90% CI 79.52 to 156.93
  • T2DM Normal Renal Function vs T2DM Mild Renal Impairment · Ratio (test/reference) of adjusted means: 120.31 · 90% CI 83.49 to 173.38
  • T2DM Normal Renal Function vs T2DM Moderate Renal Impairment · Ratio (test/reference) of adjusted means: 134.18 · 90% CI 94.46 to 190.62
  • T2DM Normal Renal Function vs T2DM Severe Renal Impairment · Ratio (test/reference) of adjusted means: 100.99 · 90% CI 71.89 to 141.87
PrimaryArea Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-06882961

AUClast was area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.

Time frame:
0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-06882961
ng*hr/mLHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-06882961359.9 ± 30399.6 ± 50466.3 ± 19538.2 ± 44404.8 ± 46
Statistical analysis
  • Healthy and Normal Renal Function vs T2DM Normal Renal Function · Ratio (test/reference) of adjusted means: 111.02 · 90% CI 79.60 to 154.86
  • T2DM Normal Renal Function vs T2DM Mild Renal Impairment · Ratio (test/reference) of adjusted means: 116.70 · 90% CI 82.76 to 164.56
  • T2DM Normal Renal Function vs T2DM Moderate Renal Impairment · Ratio (test/reference) of adjusted means: 134.68 · 90% CI 96.56 to 187.85
  • T2DM Normal Renal Function vs T2DM Severe Renal Impairment · Ratio (test/reference) of adjusted means: 101.31 · 90% CI 72.63 to 141.30
PrimaryFraction Unbound (fu) of Plasma PF-06882961

Fu was defined as fraction of unbound drug in plasma.

Time frame:
0 (pre dose), 4 hours (post dose) on Day 1
Reported as:
Geometric mean · Ratio
Fraction Unbound (fu) of Plasma PF-06882961
RatioHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Fraction Unbound (fu) of Plasma PF-068829610.01519 ± 90.01542 ± 150.01699 ± 140.01861 ± 180.01960 ± 18
Statistical analysis
  • Healthy and Normal Renal Function vs T2DM Normal Renal Function · Ratio (test/reference) of adjusted means: 101.52 · 90% CI 88.89 to 115.94
  • T2DM Normal Renal Function vs T2DM Mild Renal Impairment · Ratio (test/reference) of adjusted means: 110.17 · 90% CI 96.05 to 126.37
  • T2DM Normal Renal Function vs T2DM Moderate Renal Impairment · Ratio (test/reference) of adjusted means: 120.63 · 90% CI 105.63 to 137.77
  • T2DM Normal Renal Function vs T2DM Severe Renal Impairment · Ratio (test/reference) of adjusted means: 127.06 · 90% CI 111.26 to 145.12
SecondaryMaximum Observed Concentration of Unbound Drug (Cmax,u) of Plasma PF-06882961

Cmax,u was defined as maximum observed concentration of unbound drug.

Time frame:
0 (pre dose), 4 hours (post dose) on Day 1
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration of Unbound Drug (Cmax,u) of Plasma PF-06882961
ng/mLHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Maximum Observed Concentration of Unbound Drug (Cmax,u) of Plasma PF-068829610.5896 ± 340.5963 ± 600.6662 ± 321.055 ± 250.7680 ± 57
SecondaryUnbound Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf,u) of Plasma PF-06882961

AUCinf,u was defined as unbound area under the plasma concentration-time profile from time zero extrapolated to infinite time.

Time frame:
0 (pre dose), 4 hours (post dose) on Day 1
Reported as:
Geometric mean · ng*hr/mL
Unbound Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf,u) of Plasma PF-06882961
ng*hr/mLHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Unbound Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf,u) of Plasma PF-068829615.505 ± 376.246 ± 457.931 ± 1610.01 ± 318.019 ± 50
SecondaryUnbound Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,u) of Plasma PF-06882961

AUClast,u was defined as unbound area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration.

Time frame:
0 (pre dose), 4 hours (post dose) on Day 1
Reported as:
Geometric mean · ng*hr/mL
Unbound Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,u) of Plasma PF-06882961
ng*hr/mLHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Unbound Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,u) of Plasma PF-068829615.470 ± 386.162 ± 467.922 ± 1410.01 ± 307.927 ± 50
SecondaryApparent Clearance (CL/F) of Plasma PF-06882961

Apparent Clearance After Oral Dose (CL/F) was defined as apparent clearance after oral dose on the last day of treatment period.

Time frame:
0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Reported as:
Geometric mean · liter per hour (L/hr)
Apparent Clearance (CL/F) of Plasma PF-06882961
liter per hour (L/hr)Healthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Apparent Clearance (CL/F) of Plasma PF-0688296155.17 ± 3049.32 ± 4941.08 ± 1936.83 ± 4848.93 ± 46
SecondaryApparent Clearance of Unbound Drug After Oral Administration (CLu/F) of Plasma PF-06882961

CLu/F was defined as apparent clearance of unbound drug.

Time frame:
0 (pre dose), 4 hours (post dose) on Day 1
Reported as:
Geometric mean · L/hr
Apparent Clearance of Unbound Drug After Oral Administration (CLu/F) of Plasma PF-06882961
L/hrHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Apparent Clearance of Unbound Drug After Oral Administration (CLu/F) of Plasma PF-068829613631 ± 373200 ± 452525 ± 162000 ± 312494 ± 50
SecondaryApparent Volume of Distribution (Vz/F) of Plasma PF-06882961

Vz/F was defined as apparent volume of distribution.

Time frame:
0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Reported as:
Geometric mean · liter (L)
Apparent Volume of Distribution (Vz/F) of Plasma PF-06882961
liter (L)Healthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Apparent Volume of Distribution (Vz/F) of Plasma PF-06882961600.8 ± 59552.3 ± 89372.5 ± 38438.4 ± 85565.9 ± 48
SecondaryUnbound Vz/F (Vz,u/F) of Plasma PF-06882961

Vz,u/F was defined as apparent volume of distribution of unbound drug.

Time frame:
0 (pre dose), 4 hours (post dose) on Day 1
Reported as:
Geometric mean · Liter
Unbound Vz/F (Vz,u/F) of Plasma PF-06882961
LiterHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Unbound Vz/F (Vz,u/F) of Plasma PF-0688296139530 ± 6835810 ± 8422890 ± 3023800 ± 6328900 ± 51
SecondaryTime of Observed Maximum Plasma Concentration (Tmax) of Plasma PF-06882961

Tmax was defined as time to maximum observed concentration. Observed directly from data as time of first occurrence.

Time frame:
0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Reported as:
Median · hour (hr)
Time of Observed Maximum Plasma Concentration (Tmax) of Plasma PF-06882961
hour (hr)Healthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Time of Observed Maximum Plasma Concentration (Tmax) of Plasma PF-068829615.00 (3.00 to 8.00)5.00 (5.00 to 8.13)6.00 (3.00 to 12.0)5.50 (4.00 to 6.00)5.00 (4.00 to 6.00)
SecondaryTerminal Elimination Half-Life (T1/2) of Plasma PF-06882961

Plasma terminal elimination half-life (T1/2) is the time measured for the plasma concentration to decrease by one half at the terminal phase.

Time frame:
0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Reported as:
Mean · hr
Terminal Elimination Half-Life (T1/2) of Plasma PF-06882961
hrHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Terminal Elimination Half-Life (T1/2) of Plasma PF-068829618.111 ± 3.48288.139 ± 2.56406.640 ± 2.65518.907 ± 4.04978.058 ± 0.84962
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse event (TEAE) means event between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of death; inpatient hospitalization; life-threatening experience; disability; congenital anomaly or deemed significant for any other reason.

Time frame:
From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities)
ParticipantsHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Participants with adverse events16122
Participants with serious adverse events00000
Participants with severe adverse events00000
Participants discontinued from study due to adverse events00000
Participants discontinued study drug due to AE and continue Study00000
Participants with dose reduced or temporary discontinuation due to adverse events00000
SecondaryNumber of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

Laboratory test abnormalities included hematology, chemistry and urinalysis.

Time frame:
From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
Hematology: Erythrocytes (10^6/mm^3) < 0.8x LLN00001
Hematology: Ery. Mean Corpuscular HGB Concentration (g/dL) < 0.9x LLN00200
Hematology: Lymphocytes (10^3/mm^3) < 0.8x LLN00001
Hematology: Eosinophils (10^3/mm^3) > 1.2x ULN00110
Clinical Chemistry: Bilirubin (mg/dL) > 1.5x ULN10000
Clinical Chemistry: Blood Urea Nitrogen (mg/dL) > 1.3x ULN00458
Clinical Chemistry: Creatinine (mg/dL) > 1.3x ULN00038
Clinical Chemistry: Urate (mg/dL) > 1.2x ULN00110
Clinical Chemistry: Magnesium (mg/dL) < 0.9x LLN00010
Clinical Chemistry: Phosphate (mg/dL) > 1.2x ULN00002
Clinical Chemistry: Bicarbonate (mEq/L) < 0.9x LLN00001
Clinical Chemistry: Glucose (mg/dL) > 1.5x ULN04353
Clinical Chemistry: Triacylglycerol Lipase (U/L) > 1.5x ULN02012
Urinalysis: URINE Glucose (Scalar) ≥ 101222
Urinalysis: URINE Protein (Scalar) ≥ 100044
Urinalysis: Leukocyte Esterase ≥ 101001
Urinalysis: Hyaline Casts (/LPF) > 100001
Urinalysis: Bacteria (/HPF) > 2010000
SecondaryNumber of Participants With Abnormal Vital Signs

The vital signs were measured included pulse rate (beats/min) and blood pressure (mmHg).

Time frame:
From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs
ParticipantsHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
SITTING SYSTOLIC BLOOD PRESSURE (MMHG): Value < 90mmHg00000
SITTING SYSTOLIC BLOOD PRESSURE (MMHG): Chg ≥ 30mmHg increase00011
SITTING SYSTOLIC BLOOD PRESSURE (MMHG): Chg ≥ 30mmHg decrease00001
SITTING DIASTOLIC BLOOD PRESSURE (MMHG): Value < 50 mmHg00000
SITTING DIASTOLIC BLOOD PRESSURE (MMHG): Chg ≥ 20mmHg increase00111
SITTING DIASTOLIC BLOOD PRESSURE (MMHG): Chg ≥ 20mmHg decrease00000
PULSE RATE (BPM): Value < 40 bpm00000
PULSE RATE (BPM): Value > 120 bpm00000
SecondaryNumber of Participants With Abnormal Electrocardiograms (ECGs)

ECG parameters included QTCF, PR interval, and QRS interval.

Time frame:
From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiograms (ECGs)
ParticipantsHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal Impairment
PR INTERVAL NOT OTHERWISE SPECIFIED (MSEC): Value ≥ 30000000
PR INTERVAL NOT OTHERWISE SPECIFIED (MSEC): %Chg ≥ 25/50%00000
QRS INTERVAL NOT OTHERWISE SPECIFIED (MSEC): Value ≥ 14001000
QRS INTERVAL NOT OTHERWISE SPECIFIED (MSEC): %Chg ≥ 50%00000
QTCF NOT OTHERWISE SPECIFIED (MSEC): 450 < Value ≤ 48000012
QTCF NOT OTHERWISE SPECIFIED (MSEC): 480 < Value ≤ 50001000
QTCF NOT OTHERWISE SPECIFIED (MSEC): Value > 50000000
QTCF NOT OTHERWISE SPECIFIED (MSEC): 30 < Chg ≤ 6000000
QTCF NOT OTHERWISE SPECIFIED (MSEC): Chg > 6000000

Adverse events

Collected over From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy and Normal Renal Function0/8 (0%)0/8 (0%)1/8 (12.5%)
T2DM Normal Renal Function0/7 (0%)0/7 (0%)6/7 (85.7%)
T2DM Mild Renal Impairment0/8 (0%)0/8 (0%)1/8 (12.5%)
T2DM Moderate Renal Impairment0/8 (0%)0/8 (0%)2/8 (25%)
T2DM Severe Renal Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Total0/39 (0%)0/39 (0%)12/39 (30.8%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventHealthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal ImpairmentTotal
PolyuriaRenal and urinary disorders0/82/70/80/80/82/39
DiarrhoeaGastrointestinal disorders0/80/70/82/80/82/39
NauseaGastrointestinal disorders1/81/70/81/81/84/39
FatigueGeneral disorders0/81/70/80/80/81/39
Upper respiratory tract infectionInfections and infestations0/81/70/80/80/81/39
Lipase increasedInvestigations0/81/70/80/80/81/39
SARS-CoV-2 test positiveInvestigations0/81/70/80/80/81/39
Increased appetiteMetabolism and nutrition disorders0/81/70/80/80/81/39
PolydipsiaMetabolism and nutrition disorders0/81/70/80/80/81/39
HyperhidrosisSkin and subcutaneous tissue disorders0/81/70/80/80/81/39

Baseline characteristics

All enrolled participants who received at least one dose of study intervention.

Age, Continuous
Age, Continuous(Years)Healthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal ImpairmentTotal
Mean57.1 ± 2.3064.1 ± 7.1768.0 ± 10.9067.0 ± 9.0959.8 ± 4.9863.2 ± 8.31
Sex: Female, Male
Sex: Female, Male(Participants)Healthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal ImpairmentTotal
Female3454218
Male5334621
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Healthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal ImpairmentTotal
Hispanic or Latino5023414
Not Hispanic or Latino3765425
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Healthy and Normal Renal FunctionT2DM Normal Renal FunctionT2DM Mild Renal ImpairmentT2DM Moderate Renal ImpairmentT2DM Severe Renal ImpairmentTotal
White6477428
Black or African American1311410
American Indian or Alaska Native100001
08

Study locations

3 sites
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Prism Research LLC dba Nucleus Network
    Saint Paul, Minnesota 55114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Feb 2022, 13 months.

Results were first posted in May 2024, 2 years 2 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 13 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2020
First posted
Nov 4, 2020
StartActual
Jan 13, 2021
Primary completionActual
Feb 18, 2022
CompletionActual
Feb 18, 2022
Results first posted
May 10, 2024
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04616027
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 4, 2020
Start date
Jan 13, 2021
Primary completion
Feb 18, 2022
Completion
Feb 18, 2022
Results posted
May 10, 2024
Last update
May 10, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Danuglipron

Start the discussion